Sánchez CCD, Vázquez RD, Pulido DN, Godínez AL

Language: Spanish
References: 21
Page: 232-235
PDF size: 133.50 Kb.

ABSTRACT

Background: chronic inflammatory skin diseases affect quality of life. Psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS) can be evaluated using the life quality index (DLQI), which is a tool that influences the treatment and prognosis of these patients. Few studies talk have mentioned of which these diseases has the greatest impact.
Objective: to determine the difference between the quality of life of patients with hidradenitis suppurativa psoriasis vs. AD vs. HS.
Methods: a cross-sectional, comparative and prospective study in patients with moderate to severe atopic dermatitis (AD), psoriasis and hidradenitis suppurativa (HS), with systemic treatments. They underwent a DLQI questionnaire before the follow-up consultation in dermatology and subsequently the total score of DLQI and each item of the questionnaire was compared between the three diseases.
Results: a statistical difference was observed between psoriasis vs. AD and psoriasis vs. HS in most of the DLQI items (p ‹0.05). AD vs. HS only presented statistical differences in personal relationships (zero vs. four, p = 0.000).
Conclusions: in this study demonstrated that psoriasis patients have a better quality of life, followed by ad and hs patients, respectively.

REFERENCES

1. Ring J, Quality of life: an essential parameter for dermatology, JEur Acad Dermatol Venereol 2017; 31(4):573.

2. Chernyshov PV, The evolution of quality of life assessment anduse in dermatology, Dermatology 2019; 235(3):167-74.

3. Ali FM, Johns N, Salek S y Finlay AY, Correlating the dermatologylife quality index with psychiatric measures: a systematicreview, Clin Dermatol 2018; 36(6):691-7.

4. Gisondi P, Recognizing the differential impact of site of involvementon quality of life in dermatology, Br J Dermatol 2019;181(2):229-30.

5. García-Sánchez L, Montiel-Jarquín AJ, Vázquez-Cruz E, May-SalazarA, Gutiérrez-Gabriel I y Loría-Castellanos J, Calidad de vida enel paciente con psoriasis, Gac Med Mex 2017; 153:185-9.

6. Rincón-Pérez C, Larenas-Linneman D et al., Consenso mexicanopara el diagnóstico y tratamiento de la dermatitis atópicaen adolescentes y adultos, Rev Alerg Mex 2018; 65(2):s8-88.

7. Quiroz-Vergara JC, Morales-Sánchez MA, Castillo-Rojas G,López-Vidal Y, Peralta-Pedrero ML, Jurado-Santa Cruz F et al.,Diagnóstico tardío de psoriasis: motivos y consecuencias, GacMed Mex 2017; 153(3):335-43.

8. Gerdes S, Körber A, Biermann M, Karnthaler C y Reinhardt M,Absolute and relative psoriasis area and severity index (pasi)treatment goals and their association with health-related qualityof life, J Dermatolog Treat 2020; 31(5):470-5.

9. Herrera-Sánchez DA, Hernández-Ojeda M y Vivas-Rosales IJ,Estudio epidemiológico sobre dermatitis atópica en México,Rev Alerg Mex 2019; 66(2):192-204.

10. García-Valdés L, Flores-Ochoa JF, Vega-Memije ME y Arenas R,Hidrosadenitis supurativa. Parte i. Epidemiología, etiopatogenia,clínica y su diagnóstico, Dermatología Cosmética, Médica yQuirúrgica 2017; 15(3):176-83.

11. Sampogna F, Fania L, Mazzanti C, Caggiati A, Pallotta S, PanebiancoA et al., The broad-spectrum impact of hidradenitis suppurativaon quality of life: a comparison with psoriasis, Dermatology2019; 235(4):308-14.

12. Kwan Z, Bong YB, Tan LL, Lim SX, Yong ASW, Chang CC et al.,Determinants of quality of life and psychological status in adultswith psoriasis, Arch Derm Res 2018; 310(5):443-51.

13. Birdi G, Cooke R y Knibb RC, Impact of atopic dermatitis onquality of life in adults: a systematic review and meta-analysis,Int J Dermatol 2020; 59(4):e75-91.

14. Khan JM, Rathore MU, Tahir M y Abbasi T, Dermatology lifequality index in patients of psoriasis and its correlation with severityof disease, J Ayub Med Coll Abbottabad 2020; 32(1):64-7.

15. Kluger N, Sintonen H, Ranta M y Serlachius M, Health-related qualityof life of patients with hidradenitis suppurativa measured withthe 15d instrument and comparison with the general populationand patients with psoriasis, Skin Appendage Disord 2018; 4:131-5

16. Balieva F, Finlay A, Kupfer J, Aragones L, Lien L, Gieler U et al.,The role of therapy in impairing quality of life in dermatologicalpatients: a multinational study, Acta Derm Venereol 2018;98(6):563-9.

17. Farzanfar D, Dowlati Y, French LE, Lowes MA y Alavi A, Inflammation:a contributor to depressive comorbidity in inflammatoryskin disease, Skin Pharmacol Physiol 2018; 31(5):246-51.

18. Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB,Svensson A, Manolache L et al., Quality of life measurementin hidradenitis suppurativa: position statement of the EuropeanAcademy of Dermatology and Venereology task forces on qualityof life and patient-oriented outcomes and acne, rosacea andhidradenitis suppurativa, J Eur Acad Dermatol Venereol 2019;33(9):1633-43.

19. Lundberg L, Johannesson M, Silverdahl M, Hermansson C yLindberg M, Health-related quality of life in patients with psoriasisand atopic dermatitis measured with sf-36, dlqi and a subjectivemeasure of disease activity, Acta Derm Venereol 2000;80(6):430-4.

20. Kluger N, Sintonen H, Ranta M y Serlachius M, Health-relatedquality of life of patients with hidradenitis suppurativa measuredwith the 15d instrument and comparison with the generalpopulation and patients with psoriasis, Skin Appendage Disord2018; 4(3):131-5.

21. Sampogna F, Fania L, Mazzanti C, Caggiati A, Pallotta S, PanebiancoA, Mastroeni S, Didona B, Pintori G y Abeni D, The broadspectrumimpact of hidradenitis suppurativa on quality of life:a comparison with psoriasis, Dermatology 2019; 235(4):308-4.